Ahmad R - Search Results

1

In vivo type 1 cannabinoid receptor availability in Alzheimer's disease.

Ahmad R, Goffin K, Van den Stock J, De Winter FL, Cleeren E, Bormans G, Tournoy J, Persoons P, Van Laere K, Vandenbulcke M. Ahmad R, et al. Eur Neuropsychopharmacol. 2014 Feb;24(2):242-50. doi: 10.1016/j.euroneuro.2013.10.002. Epub 2013 Oct 17. Eur Neuropsychopharmacol. 2014. PMID: 24189376

2

Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease.

Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K. Ahmad R, et al. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2219-2227. doi: 10.1007/s00259-016-3457-7. Epub 2016 Aug 3. Eur J Nucl Med Mol Imaging. 2016. PMID: 27488857

3

Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Ceccarini J, Casteels C, Ahmad R, Crabbé M, Van de Vliet L, Vanhaute H, Vandenbulcke M, Vandenberghe W, Van Laere K. Ceccarini J, et al. Among authors: ahmad r. Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2348-2357. doi: 10.1007/s00259-019-04445-x. Epub 2019 Jul 24. Eur J Nucl Med Mol Imaging. 2019. PMID: 31342135

4

Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects.

Ahmad R, Koole M, Evens N, Serdons K, Verbruggen A, Bormans G, Van Laere K. Ahmad R, et al. Mol Imaging Biol. 2013 Aug;15(4):384-90. doi: 10.1007/s11307-013-0626-y. Mol Imaging Biol. 2013. PMID: 23508466 Clinical Trial.

5

Functional brain changes underlying irritability in premanifest Huntington's disease.

Van den Stock J, De Winter FL, Ahmad R, Sunaert S, Van Laere K, Vandenberghe W, Vandenbulcke M. Van den Stock J, et al. Among authors: ahmad r. Hum Brain Mapp. 2015 Jul;36(7):2681-90. doi: 10.1002/hbm.22799. Epub 2015 Apr 8. Hum Brain Mapp. 2015. PMID: 25858294 Free PMC article.

6

Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.

Koole M, Van Laere K, Ahmad R, Ceccarini J, Bormans G, Vandenberghe W. Koole M, et al. Among authors: ahmad r. Mov Disord. 2017 Jun;32(6):943-945. doi: 10.1002/mds.27005. Epub 2017 Apr 10. Mov Disord. 2017. PMID: 28394032 No abstract available.

7

Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CB₁R Levels.

Ceccarini J, Ahmad R, Van de Vliet L, Casteels C, Vandenbulcke M, Vandenberghe W, Van Laere K. Ceccarini J, et al. Among authors: ahmad r. J Nucl Med. 2019 Jan;60(1):115-121. doi: 10.2967/jnumed.118.210393. Epub 2018 Jun 22. J Nucl Med. 2019. PMID: 29934407 Free article.

8

Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging.

Van Laere K, Ahmad RU, Hudyana H, Celen S, Dubois K, Schmidt ME, Bormans G, Koole M. Van Laere K, et al. Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):254-61. doi: 10.1007/s00259-012-2270-1. Epub 2012 Nov 16. Eur J Nucl Med Mol Imaging. 2013. PMID: 23160998

9

Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.

Van Laere K, Ahmad RU, Hudyana H, Dubois K, Schmidt ME, Celen S, Bormans G, Koole M. Van Laere K, et al. J Nucl Med. 2013 Aug;54(8):1285-93. doi: 10.2967/jnumed.112.118679. Epub 2013 Jul 10. J Nucl Med. 2013. PMID: 23843566 Free article. Clinical Trial.

10

PET imaging shows loss of striatal PDE10A in patients with Huntington disease.

Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, Vandenberghe W. Ahmad R, et al. Neurology. 2014 Jan 21;82(3):279-81. doi: 10.1212/WNL.0000000000000037. Epub 2013 Dec 18. Neurology. 2014. PMID: 24353339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,457 results

Search Page

Filters